Finally, there is a series of annexes dealing with geographical distribution of lymphatic filariasis, onchocerciasis, schistosomiasis and soil transmitted helminthiasis, strategies for rapid assessment, standardized forms for recording serious adverse experiences
, drug supply, recommended dosages and dose poles, coverage forms and disease specific information.
A total of 69% of patients in each group reported at least one adverse experience, and 1.6% of each group discontinued the medication due to serious adverse experiences
. During the course of the therapy and up to 14 days' follow-up, 6 patients in the ertapenem group died, compared with 10 patients in the piperacillin/tazobactam group.